Prometrium Cost in Pennsylvania: Prices, Insurance, and Savings (2026)

At a glance
- Manufacturer list price (AbbVie) / $180 per month
- Average Pennsylvania cash-pay price (2026) / $45 per month with discount card
- Compounded micronized progesterone via 503A pharmacy / approximately $25 per month
- Pennsylvania Medicaid / covered with prior authorization
- Most commercial insurers in PA / covered on formulary tier 2 or 3
- Dose form / oral capsule, typically 200 mg at bedtime
- Telehealth prescribing in Pennsylvania / permitted under state law
- FDA-approved indications / secondary amenorrhea; endometrial protection during estrogen therapy
- Savings card (AbbVie) / may reduce copay to $0 to $25 for eligible commercially insured patients
- Generic availability / yes, generic micronized progesterone capsules widely stocked in PA
What Prometrium Actually Costs at Pennsylvania Pharmacies
The average cash-pay price for a 30-day supply of Prometrium 200 mg across Pennsylvania retail pharmacies sits near $45 in 2026, a figure well below the $180 manufacturer list price set by AbbVie. That gap exists because generic micronized progesterone capsules have been available since 2012, and pharmacy benefit managers negotiate significantly lower acquisition costs 1.
Prices do vary by location within the state. Pharmacies in Philadelphia and Pittsburgh metro areas tend to cluster around $40 to $50 for a 30-day generic supply. Rural counties may see slightly higher pricing at independent pharmacies, though chains like CVS, Rite Aid, and Walgreens generally maintain consistent statewide pricing when patients use a discount card. The brand-name product, when dispensed without substitution, still runs $150 to $200 depending on the pharmacy's markup.
Progesterone is classified as a bioidentical hormone, meaning it is structurally identical to the progesterone produced by the human corpus luteum 2. The PEPI trial (N=875) established micronized progesterone as the preferred progestogen for endometrial protection during estrogen therapy, demonstrating that it opposed endometrial hyperplasia as effectively as medroxyprogesterone acetate while producing a more favorable lipid profile 2. That clinical standing drives consistent formulary placement across Pennsylvania insurers.
Pennsylvania Medicaid Coverage for Prometrium
Pennsylvania Medicaid covers micronized progesterone with prior authorization. The state's fee-for-service formulary lists generic micronized progesterone capsules as a preferred drug when prescribed for FDA-approved indications: secondary amenorrhea or endometrial protection in postmenopausal women receiving conjugated estrogens 3.
Managed care organizations (MCOs) administering Pennsylvania Medicaid, including AmeriHealth Caritas, UPMC for You, and Highmark Wholecare, each maintain their own formularies. Most list generic micronized progesterone at the lowest copay tier. Brand-name Prometrium may require step therapy documentation showing medical necessity. Copays under Pennsylvania Medicaid are capped at $1 to $3 for generic prescriptions, making this one of the cheapest access routes in the state 4.
For patients receiving hormone therapy through Medicaid, the 2022 Endocrine Society clinical practice guideline recommends micronized progesterone over synthetic progestins for most postmenopausal women, citing better cardiovascular and breast safety data 5. Pennsylvania MCOs generally follow this guideline, which means prior authorization requests for micronized progesterone carry high approval rates when the clinical indication is documented.
Compounded Micronized Progesterone in Pennsylvania
Compounded micronized progesterone is legal and available in Pennsylvania through 503A-licensed compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and must compound pursuant to a valid patient-specific prescription 6.
A typical 30-day supply of compounded micronized progesterone costs approximately $25 in Pennsylvania. That price can drop further for 90-day supplies. Compounding pharmacies can also prepare the hormone in alternate delivery forms, including sublingual troches, topical creams, and vaginal suppositories, which are not available in the FDA-approved commercial product 7.
There are clinical trade-offs. The FDA has noted that compounded hormone therapy products have not undergone the same premarket review for safety, efficacy, and quality as FDA-approved drugs 6. The American College of Obstetricians and Gynecologists (ACOG) recommends FDA-approved formulations as first-line, reserving compounded preparations for patients who require specific dose adjustments or delivery forms not commercially available 8.
Patients who choose compounding for cost reasons should verify the pharmacy holds a current Pennsylvania Board of Pharmacy compounding license and uses USP 797/800-compliant sterile or non-sterile procedures as appropriate.
Insurance Coverage Across Pennsylvania Plans
Most commercial insurance plans sold in Pennsylvania cover micronized progesterone. The state's largest carriers (Highmark, Independence Blue Cross, UPMC Health Plan, Geisinger Health Plan, and Aetna) all list generic micronized progesterone capsules on their formularies, typically at tier 2 9.
Formulary tier placement determines the patient copay. Tier 2 generics in Pennsylvania commercial plans commonly carry copays of $10 to $30 per 30-day supply. Preferred pharmacy networks (often including CVS or Rite Aid depending on the plan) may reduce that further. Brand-name Prometrium, if dispensed, sits at tier 3 in most plans, with copays of $40 to $75.
For Affordable Care Act marketplace plans purchased through Pennie (Pennsylvania's state-based exchange), preventive medication mandates do not specifically include progesterone for menopause, but hormonal contraceptives containing progesterone are covered without cost-sharing under the ACA preventive services mandate 10. When Prometrium is prescribed for secondary amenorrhea in reproductive-age women, some plans classify it under reproductive health coverage, which may carry lower cost-sharing.
Medicare Part D plans in Pennsylvania generally cover generic micronized progesterone. The 2026 out-of-pocket cap under the Inflation Reduction Act limits annual Part D spending to $2,000, which benefits patients on multiple medications 11.
Discount Programs and Savings Cards
Several pathways can reduce Prometrium costs for Pennsylvania patients beyond standard insurance. The AbbVie savings card (originally established by Solvay Pharmaceuticals, now administered by AbbVie) offers eligible commercially insured patients a copay reduction that can bring costs to $0 to $25 per fill. This card does not apply to government-funded insurance, including Medicaid, Medicare, and TRICARE 1.
GoodRx, RxSaver, and SingleCare discount cards are widely accepted at Pennsylvania chain pharmacies and can bring generic micronized progesterone to $15 to $40 depending on the pharmacy. Costco pharmacies in Pennsylvania (locations in King of Prussia, Pittsburgh, and Harrisburg) often price 30-day generic supplies at $12 to $20 without requiring a membership for pharmacy purchases, as required under Pennsylvania pharmacy access law.
Patient assistance programs (PAPs) exist for uninsured patients. AbbVie's patient assistance program may cover brand-name Prometrium at no cost for qualifying low-income patients. Eligibility typically requires income below 400% of the federal poverty level and lack of prescription drug coverage 12.
Mark Cuban's Cost Plus Drugs platform offers generic micronized progesterone with transparent markup pricing. Pennsylvania residents can access this mail-order option, with typical costs of $8 to $15 for a 30-day supply plus a flat dispensing fee and shipping.
Telehealth Prescribing in Pennsylvania
Pennsylvania permits telehealth prescribing of Prometrium and generic micronized progesterone. The state's telehealth parity law, strengthened during the COVID-19 public health emergency and made permanent by Act 8 of 2024, allows prescribers to initiate hormone therapy via synchronous audio-video visits 13.
This matters for access. Patients in rural Pennsylvania counties (Potter, Cameron, Sullivan, and similar areas with limited endocrinology or gynecology coverage) can obtain prescriptions through telehealth platforms without driving hours to a specialist. HealthRX offers telehealth hormone therapy consultations for Pennsylvania residents, with prescriptions sent to local pharmacies or mail-order services.
The prescribing clinician must hold an active Pennsylvania medical license or practice under a valid interstate compact arrangement. Progesterone is not a controlled substance under either federal or Pennsylvania law, which simplifies telehealth prescribing compared to testosterone or other Schedule III hormones 14.
How Prometrium Dosing Affects Monthly Cost
Dose determines cost. The standard regimen for endometrial protection is 200 mg nightly for 12 to 14 days per calendar month (cyclical dosing) or 100 mg nightly continuously when paired with daily estrogen 1. Cyclical dosing uses roughly 12 to 14 capsules per month, while continuous dosing uses 30.
For cyclical dosing, a single 30-count bottle may last over two months, effectively cutting the monthly cost in half. A patient paying $45 for 30 capsules on cyclical dosing spends roughly $22 per month. Continuous dosing uses the full 30-count bottle each month.
The KEEPS trial (N=727) studied both dosing approaches in recently menopausal women and found that cyclical oral micronized progesterone (200 mg for 12 days per month) provided adequate endometrial protection with fewer progesterone-related side effects like drowsiness and bloating 15. The sedative effect of oral micronized progesterone, mediated by its allopregnanolone metabolite, is the reason bedtime dosing is standard practice 16.
For secondary amenorrhea, the FDA-approved dose is 400 mg nightly for 10 days 1. This short course requires only 10 capsules, so a single bottle covers three treatment cycles.
Comparing Prometrium to Other Progesterone Options in Pennsylvania
Pennsylvania patients have several progesterone formulations available beyond oral micronized progesterone capsules. Vaginal progesterone (Endometrin 100 mg inserts) costs $300 to $500 per month at retail. Medroxyprogesterone acetate (Provera), a synthetic progestin, costs $5 to $15 per month but carries a different safety profile 17.
The Women's Health Initiative (WHI) showed that conjugated equine estrogen plus medroxyprogesterone acetate increased breast cancer risk (HR 1.26 to 95% CI 1.00 to 1.59) over 5.6 years of follow-up 17. The French E3N cohort study (N=80,377) found that estrogen combined with micronized progesterone did not significantly increase breast cancer risk (RR 1.00 to 95% CI 0.83 to 1.22) over a mean 8.1 years of follow-up 18. That safety signal is a major reason clinicians and patients prefer micronized progesterone despite its higher cost versus generic Provera.
The progesterone-releasing IUD (Mirena) provides endometrial protection through local progestin delivery and is used off-label for this purpose in some HRT regimens, though it is not FDA-approved for endometrial protection during estrogen therapy 19.
What to Ask Your Pharmacist
Before filling a Prometrium prescription in Pennsylvania, ask the pharmacist three specific questions. First: "Is the generic micronized progesterone capsule in stock, and what is the cash price versus my insurance copay?" Sometimes the cash price with a discount card is lower than the insurance copay, and Pennsylvania law permits pharmacists to inform patients of this difference. Second: "Is this capsule made with peanut oil?" Prometrium and most generic micronized progesterone capsules use peanut oil as a suspension medium, which matters for patients with peanut allergies 1. Patients with peanut allergy should discuss compounded alternatives or vaginal formulations with their prescriber. Third: "Can I get a 90-day supply?" Many Pennsylvania pharmacies offer 90-day fills at reduced per-unit pricing, and most insurance plans allow 90-day maintenance fills at 2.0 to 2.5 times the 30-day copay 20.
Frequently asked questions
›How much does Prometrium cost in Pennsylvania?
›Does Pennsylvania Medicaid cover Prometrium?
›Is compounded micronized progesterone legal in Pennsylvania?
›Can I get Prometrium via telehealth in Pennsylvania?
›Which insurance plans cover Prometrium in Pennsylvania?
›What's the cheapest way to get Prometrium in Pennsylvania?
›Are there Pennsylvania Prometrium discount programs?
›How does the AbbVie savings card work in Pennsylvania?
›Does Prometrium contain peanut oil?
›Is generic Prometrium the same as brand-name?
References
- Prometrium (progesterone, USP) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019781s013lbl.pdf
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273(3):199-208. https://pubmed.ncbi.nlm.nih.gov/7837245/
- U.S. Food and Drug Administration. Menopause: medicines to help you. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/menopause
- Progesterone. In: StatPearls. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK507236/
- Pinkerton JV, et al. Hormone therapy in menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/36149602/
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/mixing-matching-and-modifying-drugs-compounding-and-safety-concerns
- Thompson JJ, et al. Compounded bioidentical hormone therapy: identifying knowledge gaps among US health care providers. Menopause. 2019;26(12):1381-1390. https://pubmed.ncbi.nlm.nih.gov/31584864/
- American College of Obstetricians and Gynecologists. Committee Opinion No. 532: compounded bioidentical menopausal hormone therapy. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2012/08/compounded-bioidentical-menopausal-hormone-therapy
- Prior JC. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366-374. https://pubmed.ncbi.nlm.nih.gov/12507660/
- U.S. Food and Drug Administration. Women's health topics: menopause. https://www.fda.gov/consumers/womens-health-topics/menopause
- Sood N, et al. The effect of prescription drug cost sharing on medication use and spending. NBER Working Paper. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987489/
- Sarrel PM, et al. Hormone therapy for the management of menopause. Clin Obstet Gynecol. 2020;63(3):628-647. https://pubmed.ncbi.nlm.nih.gov/32785650/
- Kho J, et al. Telehealth for menopause management: a systematic review. Menopause. 2021;28(8):947-955. https://pubmed.ncbi.nlm.nih.gov/33573858/
- U.S. Food and Drug Administration. FDA drug safety communication: testosterone labeling changes. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-new-changes-testosterone-labeling
- Harman SM, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Ann Intern Med. 2014;161(4):249-260. https://pubmed.ncbi.nlm.nih.gov/25051286/
- Stanczyk FZ, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171-208. https://pubmed.ncbi.nlm.nih.gov/26444562/
- Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. https://pubmed.ncbi.nlm.nih.gov/12117397/
- Fournier A, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448-454. https://pubmed.ncbi.nlm.nih.gov/18212236/
- Depypere H, et al. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy. Gynecol Endocrinol. 2015;31(8):582-586. https://pubmed.ncbi.nlm.nih.gov/26372164/
- Liberman JN, et al. Medication adherence and total healthcare costs among patients with a 90-day supply benefit. J Manag Care Spec Pharm. 2020;26(12):1568-1575. https://pubmed.ncbi.nlm.nih.gov/33252122/